Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sulfiredoxin-1 (SRXN1)
- Target
- SRXN1
- Molecular classification
- Enzyme, Oxidoreductase
01
Overview
Sulfiredoxin-1 (SRXN1) is an evolutionarily conserved redox-regulatory enzyme that plays a central role in restoring the activity of antioxidant proteins, particularly 2-Cys peroxiredoxins, under oxidative stress. It catalyzes the ATP-dependent reduction of cysteine sulfinic acid in peroxiredoxins, regenerating their peroxidase activity and maintaining cellular redox homeostasis. SRXN1 participates in deglutathionylation reactions, further contributing to the regulation of redox-mediated signaling. Its aberrant expression has been linked to cancer progression, therapeutic resistance, and poor prognosis, making it both a biomarker and a potential therapeutic target, especially in contexts of redox imbalance.
- Other names
- Sulfiredoxin 1SRXN1C20orf139SRXSRX1Npn3SrxYKL086WdJ850E9.2sulphiredoxinNPN3C20ORF139
02
Mechanism of action
Drugs targeting SRXN1 would potentially act as enzyme inhibitors to block the reduction/regeneration of hyperoxidized peroxiredoxins, leading to enhanced oxidative stress and potential sensitization of cancer cells to therapy
03
Biological functions
Redox regulationResponse to oxidative stressRestoration of antioxidant protein functionDeglutathionylation of proteinsRegulation of redox-mediated signal transduction
04
Disease associations
Cancer (involved in proliferation, invasion, metastasis, resistance to treatment)Oxidative stress-related diseasesLung injury and fibrotic lung disease
05
Safety considerations
Potential risk if broadly inhibited: increased oxidative stress and tissue damage in non-cancer tissuesPossible influence on normal antioxidant defense
06
Biomarkers
Elevated SRXN1 expression as a prognostic biomarker in cancers (colorectal, hepatocellular carcinoma, esophageal squamous cell carcinoma, cervical, prostate)Possible marker for radiotherapy response in prostate cancer
Beyond the preview
Go deeper on Sulfiredoxin-1 (SRXN1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sulfiredoxin-1 (SRXN1).